Oaktree Specialty Lending’s second quarter results reflected ongoing efforts to reduce portfolio risk and maintain balance sheet flexibility, even as revenue declined compared to last year. Management emphasized that the main drivers were lower non-accruals and selective investment deployment, highlighting the successful exit of several challenged positions, notably Thrasio. President Mathew Pendo commented, "More than 85% of the decline in non-accrual dollars over the past year is due to proceeds received and investments returning to accrual status," underscoring the company’s focus on capital recovery and risk control.

Is now the time to buy OCSL? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Oaktree Specialty Lending’s Q2 Earnings Call

• Richard Shane (JPMorgan) asked how macroeconomic headwinds and tighter competition affect Oaktree’s ability to extract higher returns. CEO Armen Panossian replied that the environment is not yet at peak opportunity, and the firm remains defensive, anticipating greater volatility ahead.
• Finian O'Shea (Wells Fargo Securities) questioned the relative attractiveness of sponsor-backed versus other exposures. Panossian explained that private credit currently offers better relative value than public credit, and the company is selectively pursuing asset-backed finance where appropriate.
• O'Shea (Wells Fargo Securities) followed up on the topic of industry consolidation. Panossian and President Mathew Pendo clarified that while consolidation is occurring, large-scale acquisitions are not a critical priority, though the firm remains open to selective opportunities.
• Peter Troisi (Barclays) asked how rating agencies might view the trade-off between lower non-accruals and higher realized losses this quarter. CFO Christopher McKown responded that while realized losses are never ideal, these were largely from legacy issues and were offset by progress in reducing non-accruals and maintaining stable net asset value.
• No further analyst questions on the call.

Catalysts in Upcoming Quarters

For upcoming quarters, the StockStory team is monitoring (1) the pace of further non-accrual reductions and successful portfolio workouts, (2) management’s ability to deploy capital as market volatility creates new opportunities, and (3) the impact of persistent high interest rates on borrower performance. Additionally, trends in private credit deal flow and outcomes from potential secondary portfolio purchases or industry consolidation will be key markers of execution.

Oaktree Specialty Lending currently trades at $12.79, up from $12.13 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.